IFNG and neoplasm: In addition to the reduction of their immunogenicity, tumor cells can evade IFN-γ-dependent immune responses by altering their IFN-γ signaling pathway (e.g., via downregulation or loss of IFN-γ receptor/downstream signaling molecules or through amplification of IFN-γ pathway inhibitors).